Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib

Active, not recruitingOBSERVATIONAL

Enrollment

453

Participants

Timeline

Start Date

June 27, 2014

Primary Completion Date

February 27, 2020

Study Completion Date

November 30, 2025

Conditions

Thyroid Carcinoma

Interventions

DRUG

Sorafenib (Nexavar, BAY43-9006)

Patients treated by Physician with Nexavar under approved local prescriptions

Trial Locations (1)

Multiple Locations